The SLC30A8 gene encodes zinc transporter 8¹¹ zinc transporter 8
ZnT8 is a transmembrane protein that pumps zinc ions from the cytoplasm into insulin secretory granules inside pancreatic beta cells (ZnT8), a protein found almost exclusively in the insulin-producing beta cells of the pancreas. Its job is simple but critical: load zinc into the granules where insulin is stored. Zinc is essential for insulin to crystallize into its stable hexameric form — without adequate zinc, insulin is less stable, harder to store, and released less efficiently.

The rs13266634 variant changes a single amino acid at position 325 from arginine (encoded by the common C allele) to tryptophan (encoded by the T allele). This was one of the first type 2 diabetes risk loci identified by genome-wide association²² genome-wide association
Sladek R et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature, 2007, and it carries an unusual twist: the common allele (C, found in ~70% of people globally) is the risk allele, while the less common T allele is protective.

The Mechanism

ZnT8 sits in the membrane of insulin secretory granules and actively pumps zinc ions³³ zinc ions
Each insulin hexamer contains two Zn2+ ions at its core; roughly 70% of beta cell zinc resides in these granules into these compartments. Inside the granule, two zinc ions bind six insulin molecules to form a crystalline hexamer — the storage form of insulin. This crystallization increases storage capacity and protects insulin from premature degradation.

The Arg325 (C allele) and Trp325 (T allele) forms of ZnT8 differ in their zinc transport efficiency. Counterintuitively, the Arg325 version associated with the common C risk allele appears to transport zinc at higher capacity, yet carriers show impaired insulin processing⁴⁴ impaired insulin processing
Including elevated proinsulin-to-insulin ratios, suggesting that excess zinc granule loading may paradoxically interfere with the conversion of proinsulin to mature insulin and reduced first-phase insulin release. The Trp325 variant (T allele) has reduced transport activity but is associated with better insulin secretion dynamics.

This paradox was dramatically underscored when Flannick and colleagues⁵⁵ Flannick and colleagues
Flannick J et al. Loss-of-function mutations in SLC30A8 protect against type 2 diabetes. Nat Genet, 2014 discovered that rare complete loss-of-function mutations in SLC30A8 confer a striking 65% reduction in type 2 diabetes risk. This inverted the prevailing assumption that more ZnT8 activity equals better insulin function, and established ZnT8 inhibition as a potential therapeutic target.

The Evidence

The original GWAS⁶⁶ original GWAS
Sladek R et al. Nature, 2007 identified rs13266634 in a French cohort, and replication was swift. A meta-analysis of 46 studies⁷⁷ meta-analysis of 46 studies
Fan M et al. Association of SLC30A8 gene polymorphism with type 2 diabetes, evidence from 46 studies. Endocrine, 2016 encompassing 71,890 cases and 96,753 controls confirmed the association across European, Asian, and African populations with an odds ratio of approximately 1.15 per C allele (CC vs TT: OR ~1.53).

The EUGENE2 study⁸⁸ EUGENE2 study
Staiger H et al. The common SLC30A8 Arg325Trp variant is associated with reduced first-phase insulin release. Diabetologia, 2008 showed that CC homozygotes had a 19% decrease in first-phase insulin release during intravenous glucose tolerance testing compared to T allele carriers, providing a functional mechanism linking genotype to diabetes risk.

Critically, the relationship between this variant and diabetes risk is modifiable by zinc status. Chu and colleagues⁹⁹ Chu and colleagues
Chu A et al. Interactions between zinc transporter-8 gene and plasma zinc concentrations for impaired glucose regulation and type 2 diabetes. Diabetes, 2014 found that each 10 ug/dL increase in plasma zinc was associated with 22% lower odds of type 2 diabetes in TT carriers, 17% lower in CT carriers, but only 7% lower in CC carriers — a significant gene-nutrient interaction.

A zinc supplementation trial¹⁰¹⁰ zinc supplementation trial
Maruthur NM et al. Effect of zinc supplementation on insulin secretion: interaction between zinc and SLC30A8 genotype in Old Order Amish. Diabetologia, 2015 in 55 non-diabetic Amish individuals found that after 14 days of zinc supplementation (50 mg elemental zinc twice daily), carriers of the T allele experienced a 26% increase in early insulin response to glucose at 5 minutes compared to CC homozygotes — the first direct evidence that zinc supplementation can differentially improve beta cell function based on SLC30A8 genotype.

Practical Implications

This SNP sits at the intersection of genetics and nutrition. The key insight is that zinc status matters more for some genotypes than others. CC homozygotes have the highest baseline diabetes risk but show the smallest benefit from zinc optimization, while T allele carriers — who already have lower risk — get the most benefit from adequate zinc intake.

For everyone, ensuring adequate zinc intake supports insulin function. Good dietary sources include oysters, red meat, poultry, beans, nuts, and pumpkin seeds. For CC homozygotes, the focus should extend beyond zinc to broader metabolic health: maintaining a healthy weight, regular physical activity, and monitoring blood glucose are important given the modestly elevated diabetes risk.

Interactions

SLC30A8 rs13266634 interacts with other type 2 diabetes risk loci. The combination of the CC genotype here with TCF7L2 rs7903146 risk alleles (TT or CT) compounds overall diabetes risk through independent but converging pathways — SLC30A8 affecting insulin storage and release, TCF7L2 affecting beta cell development and incretin signaling. Individuals carrying risk alleles at both loci should be especially vigilant about metabolic health monitoring.

The SLC30A8 variant also influences ZnT8 autoantibody specificity in type 1 diabetes. The Arg325 (C allele) form is the dominant autoantibody target. While this does not change the type 2 diabetes risk interpretation, it adds a layer of immunological significance to this variant.

Adiponectin is the body's most abundant adipokine — a hormone secreted almost exclusively by adipose tissue¹¹ hormone secreted almost exclusively by adipose tissue
it activates AMPK in muscle and liver, suppresses hepatic glucose output, and reduces vascular inflammation that acts as a master regulator of insulin sensitivity, lipid metabolism, and metabolic inflammation. Low circulating adiponectin is one of the most consistent biomarkers of metabolic dysfunction, predicting insulin resistance, type 2 diabetes, NAFLD, and cardiovascular disease independently of BMI. The ADIPOQ gene on chromosome 3 encodes this protein, and variation across the locus — particularly in two linkage disequilibrium blocks spanning the promoter and intron 1 — accounts for a meaningful portion of inter-individual differences in circulating adiponectin.

rs16861205 (chr3:186,843,845 GRCh38) sits in intron 1 of ADIPOQ, within the same linkage disequilibrium block as the promoter variant rs266729. Because rs16861205 and rs266729 are in LD, some of their phenotypic associations overlap — but studies that genotyped both simultaneously demonstrate that rs16861205 has independent contributions to adiponectin dynamics and body weight regulation.

The Mechanism

Intronic variants in ADIPOQ intron 1 may influence gene expression via several mechanisms: disruption of intronic regulatory elements²² regulatory elements
sequences within introns that bind transcription factors or modulate chromatin accessibility, altered pre-mRNA splicing kinetics, or tagging of functional variants in the local LD block. rs16861205 (G>A) is an intron variant catalogued in dbSNP Build 157 with no direct protein-coding consequence. Its functional role is thought to be regulatory — either through direct intronic regulatory activity or as a haplotype tag for the broader LD block 1, which contains the promoter.

The haplotype block containing rs16861205 and rs266729 spans the region approximately −14,811 to −4,120 base pairs relative to the ADIPOQ transcription start, covering the proximal promoter and intron 1. Variants in this block collectively influence ADIPOQ transcriptional activity and circulating adiponectin levels. Because rs16861205 participates in this block, its A allele may tag a local chromatin state that alters adiponectin expression — and the gender-specific effects observed in African American cohorts suggest the regulatory influence may be modulated by sex hormone signalling on ADIPOQ transcription.

The Evidence

The most informative data come from two independent cohorts. In the Finnish Diabetes Prevention Study³³ Finnish Diabetes Prevention Study
n=507 overweight subjects with impaired glucose tolerance randomised to intensive lifestyle intervention vs control; Siitonen et al. 2011, rs16861205 was significantly associated with baseline body weight (GG carriers: 87.7 kg vs. GA/AA carriers: 84.3 kg, dominant model p=0.006) and with 4-year longitudinal weight change (additive p=0.028, dominant p=0.008). Strikingly, the A allele was associated with a greater increase in serum adiponectin concentrations over 4 years (additive p=0.040, dominant p=0.014), particularly among participants who lost weight during the first year of intervention. This suggests the A allele may reflect a distinct regulatory state in which adiponectin production is more responsive to weight loss.

A contrasting pattern was observed in the Jackson Heart Study⁴⁴ Jackson Heart Study
n=2,968 African American adults (1,131 men, 1,837 women); Davis et al. 2015 — the largest population-specific analysis of rs16861205 to date. In women, the A allele was significantly associated with lower circulating adiponectin in the fully adjusted model (beta=−0.13, SE=0.05, p=0.003). No significant association was found in men (beta=−0.11, SE=0.061, p=0.074). A gender-stratified haplotype analysis Yansane et al. 2015⁵⁵ Yansane et al. 2015 confirmed that rs16861205 participates in a haplotype block (with rs6444174, rs1403697, and rs7641507) that shows significant effects on adiponectin in women but not men.

Taken together, the evidence points to rs16861205 as a variant that modulates adiponectin levels in a sex-specific and context-dependent way. The A allele appears to reduce baseline adiponectin in women (particularly African American women) while potentially conferring greater adiponectin responsiveness to weight loss intervention.

Practical Actions

For carriers of the A allele — particularly women — the primary concern is ensuring circulating adiponectin remains within the protective range (>8 µg/mL in women,

6 µg/mL in men). The most evidence-based dietary intervention for raising adiponectin is omega-3 fatty acids: a meta-analysis of 43 randomised trials with 3,434 participants found that EPA and DHA supplementation significantly increases adiponectin, with the largest effects in individuals with low baseline levels. Replacing dietary saturated fat with monounsaturated and polyunsaturated fats activates PPARgamma in adipocytes, stimulating ADIPOQ transcription regardless of intronic genotype.

For AA homozygotes and AG women with metabolic risk factors, measuring serum adiponectin directly provides the most actionable information — it reveals whether the regulatory variant is actually suppressing output to clinically meaningful levels, and it allows monitoring of dietary intervention response over time.

Interactions

rs16861205 is in the same LD block as rs266729, the well-characterised ADIPOQ promoter variant on the platform. The combined haplotype effect of LD block 1 (rs266729 + rs16861205) on adiponectin is likely stronger than either SNP alone, but the direction of the interaction requires haplotype-level analysis. Users carrying the rs266729 G risk allele alongside the rs16861205 A allele may have the most pronounced reduction in adiponectin signalling from this LD block.

rs182052 (ADIPOQ −10066G>A), also in the platform, shows a diet-genotype interaction with monounsaturated fat intake: rs182052 G/G homozygotes increase adiponectin on a high-MUFA diet while A-allele carriers do not — making fat quality a particularly relevant modifiable factor for the broader ADIPOQ LD block.

The FADS2 gene on chromosome 11 encodes delta-6 desaturase¹¹ delta-6 desaturase
The rate-limiting enzyme that performs the first desaturation step converting dietary short-chain fatty acids (plant-based ALA and LA) into longer, biologically active forms including EPA, DHA, and arachidonic acid, the enzyme that opens the gateway to all long-chain polyunsaturated fatty acid synthesis from plant precursors. rs174616 is an intronic FADS2 variant that tags a distinct linkage disequilibrium block within the FADS1/FADS2 cluster. Carriers of the A allele produce less delta-6 desaturase activity — the enzyme that catalyzes the first rate-limiting step in both omega-3 (ALA → EPA → DHA) and omega-6 (LA → arachidonic acid) synthesis.

The Mechanism

rs174616 lies within intron 7 of the FADS2 gene at chromosome 11 position 61,861,650 (GRCh38). Like other intronic variants across the FADS cluster, it acts through a regulatory rather than coding mechanism — influencing FADS2 expression levels, and in at least one study, through associated DNA methylation changes at a CpG site (cg07999042) in the FADS2 promoter region.

The A allele reduces delta-6 desaturase output, creating a characteristic substrate-accumulation, product-deficit pattern: the precursor linoleic acid (LA) and alpha-linolenic acid (ALA) build up, while the downstream products — gamma-linolenic acid (GLA)²² gamma-linolenic acid (GLA)
First omega-6 product after FADS2 acts on linoleic acid; further elongated to DGLA then arachidonic acid, dihomo-gamma-linolenic acid (DGLA)³³ dihomo-gamma-linolenic acid (DGLA)
Omega-6 intermediate between GLA and arachidonic acid; anti-inflammatory precursor to series-1 prostaglandins, arachidonic acid (ARA), EPA, and DHA — are reduced. Because this is the first rate-limiting enzyme in the pathway, impairment ripples downstream to affect all long-chain PUFA products.

The Evidence

The foundational study for the FADS cluster is Schaeffer et al. 2006⁴⁴ Schaeffer et al. 2006
Schaeffer L et al. Common genetic variants of the FADS1 FADS2 gene cluster and their reconstructed haplotypes are associated with the fatty acid composition in phospholipids. Human Molecular Genetics, 2006, which genotyped 18 FADS1/FADS2 cluster SNPs including rs174616 in 727 German adults, demonstrating strong associations between FADS haplotypes and serum phospholipid fatty acid composition. The rs174616 A allele tagged a haplotype block independently associated with the substrate-accumulation, product-deficit PUFA signature.

Zec et al. 2020⁵⁵ Zec et al. 2020
Zec MM et al. FADS2 polymorphisms are associated with plasma arachidonic acid and estimated desaturase-5 activity in a cross-sectional study. Nutrition Research, 2020 found that the A allele was associated with lower plasma arachidonic acid and reduced estimated delta-5 desaturase activity, and identified a significant gene-diet interaction in which dietary carbohydrate percentage modified the effect on Δ6 desaturase activity.

In a case-control study of Han Chinese individuals⁶⁶ case-control study of Han Chinese individuals
Yao et al. Polymorphisms of rs174616 in the FADS1-FADS2 gene cluster is associated with a reduced risk of type 2 diabetes mellitus in northern Han Chinese people. Diabetes Res Clin Pract, 2015 (618 cases, 618 controls), the A allele was associated with a decreased conversion rate of LA to arachidonic acid (AA/LA ratio) and a modestly reduced risk of type 2 diabetes, suggesting that lower arachidonic acid production — and the resulting reduction in pro-inflammatory eicosanoids — confers some metabolic benefit in high-carbohydrate dietary contexts.

A selection genetics analysis by Romero-Hidalgo et al. 2024⁷⁷ Romero-Hidalgo et al. 2024
Romero-Hidalgo S et al. Selection scan in Native Americans of Mexico identifies FADS2 rs174616: Evidence of gene-diet interactions affecting lipid levels and Delta-6-desaturase activity. Heliyon, 2024 found that rs174616 is the most highly differentiated FADS2 SNP across global populations, with the A allele approaching fixation (94%) in Native Americans of Mexico, occurring at ~47% in Europeans and only ~19% in East Asians. This extreme population differentiation and evidence of positive selection suggest the A allele conferred a metabolic advantage in populations subsisting on high-carbohydrate, low-marine-fat diets — contexts where lower arachidonic acid production may reduce inflammatory tone.

Walle et al. 2019⁸⁸ Walle et al. 2019
Walle P et al. Liver DNA methylation of FADS2 associates with FADS2 genotype. Clinical Epigenetics, 2019 identified a mechanistic link: the rs174616 genotype was significantly associated with DNA methylation at the FADS2 CpG site cg07999042 in liver tissue, with A allele carriers showing distinct methylation patterns, providing a plausible epigenetic mechanism for how this intronic variant regulates enzyme expression.

Practical Actions

The core implication of A allele carriage is consistent with the broader FADS2 picture: dietary plant-based omega-3 (from flax, chia, walnuts) supplies ALA that requires FADS2 to begin converting toward EPA and DHA. With reduced FADS2 activity, this first conversion step is rate-limited and less EPA/DHA reaches circulation, regardless of ALA intake. Preformed EPA and DHA from fatty fish, fish oil, or algae-based supplements bypass this bottleneck entirely.

The omega-6 side matters too: reduced arachidonic acid production from dietary LA changes the balance of eicosanoid production, favoring less inflammatory signaling. Limiting excess omega-6 from refined seed oils (soybean, corn, sunflower) reduces the LA load on an already constrained FADS2 enzyme, supporting a better omega-3:omega-6 balance even when EPA/DHA are in short supply.

For vegetarians and vegans, the implications are particularly pronounced: without marine food sources, the only pathway to adequate EPA/DHA is through algae-based supplements that provide these fatty acids in preformed bioavailable form.

Interactions

rs174616 is in linkage disequilibrium with other FADS2 variants (rs174575, rs1535) and with the FADS1 delta-5 desaturase variants (rs174547, rs174537). The FADS cluster forms two linked haplotype blocks: carriers of risk alleles at rs174616 often also carry risk alleles at other cluster variants, compounding the PUFA synthesis deficit. When both FADS2 (delta-6) and FADS1 (delta-5) variants are present, the upstream deficit from FADS2 reduces substrate available for FADS1, compounding the reduction in EPA and arachidonic acid. Any APOE or cardiovascular risk variants that increase inflammatory sensitivity make adequate omega-3 status even more critical.

CYP2C9 is the primary enzyme responsible for metabolizing warfarin (Coumadin), one of the most widely prescribed and dangerous medications in clinical practice. Warfarin has an extremely narrow therapeutic window¹¹ Narrow therapeutic window: small difference between effective dose and toxic dose - too little and you risk blood clots, too much and you risk life-threatening bleeding. CYP2C9 genotype is one of the key determinants of the right dose for each individual.

The Mechanism

The CYP2C9*2 variant²² rs1799853 causes an arginine-to-cysteine substitution at position 144³³ Amino acid change: arginine to cysteine at position 144 (R144C). This amino acid change reduces the enzyme's catalytic efficiency to about 50% of normal. The enzyme is produced in normal quantities but works at roughly half speed, leading to slower clearance of warfarin and other CYP2C9 substrates. The *2 allele is most common in European populations (about 13%) and essentially absent in East Asian populations.

Warfarin Dosing Impact

Warfarin dosing is one of the most successful applications of pharmacogenomics in clinical practice. The FDA-approved warfarin label includes pharmacogenomic dosing tables based on CYP2C9 and VKORC1 genotypes. Patients with CYP2C9*2 typically need lower warfarin doses to achieve therapeutic INR levels, and they take longer to reach a stable dose. Two landmark randomized trials -- the EU-PACT trial⁴⁴ EU-PACT trial
Pirmohamed M et al. A Randomized Trial of Genotype-Guided Dosing of Warfarin. N Engl J Med, 2013 and the COAG trial⁵⁵ COAG trial
Kimmel SE et al. A Pharmacogenetic versus a Clinical Algorithm for Warfarin Dosing. N Engl J Med, 2013 -- tested genotype-guided dosing in clinical practice.

Beyond Warfarin

CYP2C9 also metabolizes phenytoin (seizure medication), NSAIDs (ibuprofen, celecoxib), and several diabetes medications (glipizide, tolbutamide). Poor metabolizers may experience increased side effects from these drugs at standard doses. For NSAIDs, the CPIC guideline⁶⁶ CPIC guideline
Theken KN et al. CPIC guideline for CYP2C9 and NSAID therapy. Clin Pharmacol Ther, 2020 recommends reduced doses or alternative agents for poor metabolizers due to increased risk of gastrointestinal bleeding.

Practical Implications

If you carry the *2 allele, this is important information for any future warfarin therapy. Pharmacogenomic-guided warfarin dosing has been shown to reduce the time to stable therapeutic dosing and decrease the risk of bleeding complications. Several online dosing calculators (like warfarindosing.org⁷⁷ warfarindosing.org
Pharmacogenomic warfarin dosing calculator) incorporate CYP2C9 genotype alongside clinical factors.

AGER encodes RAGE (Receptor for Advanced Glycation End-Products), a pattern recognition receptor¹¹ pattern recognition receptor
A cell-surface protein in the immunoglobulin superfamily that detects advanced glycation end-products, HMGB1, S100 proteins, and amyloid-beta — triggering NF-κB-mediated inflammatory gene expression found on endothelial cells, neurons, smooth muscle, immune cells, and alveolar epithelium. Unlike the Gly82Ser missense variant (rs2070600), which alters receptor structure, the −374T/A polymorphism acts upstream — it sits in the AGER promoter and directly controls how much RAGE protein is made.

The variant is catalogued on the GRCh38 plus strand with reference allele A and alternate allele T at chr6:32184610. Because AGER is transcribed from the minus strand, published papers use coding-strand notation: the common coding-strand T allele corresponds to plus-strand A, while the functional coding-strand A allele (the one studied as the promoter-active variant) corresponds to plus-strand T. The T allele on the plus strand is the allele that increases RAGE expression.

The Mechanism

In 2001, Hudson et al.²² Hudson et al.
Hudson BI et al. Effects of novel polymorphisms in the RAGE gene on transcriptional regulation and their association with diabetic retinopathy. Diabetes, 2001 used chloramphenicol acetyltransferase (CAT) reporter assays to demonstrate that the −374A coding allele (plus-strand T) increases RAGE promoter-driven transcription approximately threefold compared to the −374T coding allele (P<0.001). The mechanism involves differential binding of nuclear protein extracts from both monocyte- and hepatocyte-derived cell lines, indicating that a transcription factor or co-activator binds preferentially to the A-containing promoter sequence.

Increased RAGE transcription elevates both forms of RAGE: full-length membrane-bound RAGE and soluble RAGE (sRAGE)³³ soluble RAGE (sRAGE)
The secreted truncated form of RAGE that acts as a decoy receptor — capturing circulating AGEs and HMGB1 before they reach cell-surface RAGE, thereby damping inflammatory activation. This dual elevation creates a complex phenotype: more sRAGE circulates as a protective decoy, but more membrane-bound RAGE also sits on cell surfaces ready to fire when AGEs break through the sRAGE buffer. Under low AGE conditions, the sRAGE increase may dominate (hence the protective cardiovascular associations in non-diabetic cohorts). Under chronic hyperglycemia, where AGE loads are overwhelming, the elevated membrane RAGE amplifies inflammation more than the extra sRAGE can neutralize.

The Evidence

Transcriptional activity. The fundamental functional finding — that the −374A coding allele tripled RAGE promoter activity — was established by Hudson et al. (2001)⁴⁴ Hudson et al. (2001) and provides the mechanistic rationale for all subsequent clinical associations. This is a bona fide functional variant, not a tagging SNP.

Diabetic microvascular complications. The most replicated clinical associations involve diabetic nephropathy and retinopathy. Lindholm et al. (2006)⁵⁵ Lindholm et al. (2006)
Lindholm E et al. The −374 T/A polymorphism in the gene encoding RAGE is associated with diabetic nephropathy and retinopathy in type 1 diabetic patients. Diabetologia, 2006 studied 867 type 1 and 2,467 type 2 diabetic patients in Scandinavian cohorts and found that carrying the A/T or A/A coding genotypes (i.e., at least one T on the plus strand) associated with diabetic nephropathy (p=0.006) and sight-threatening retinopathy (p=0.03) in type 1 diabetes. A meta-analysis by Tao et al. (2017)⁶⁶ Tao et al. (2017)
Tao D et al. Association between the RAGE −374T/A gene polymorphism and diabetic retinopathy in T2DM. Rev Assoc Med Bras, 2017 combining 9 case-control studies (1,705 DR cases, 2,236 controls) found that the −374A coding allele (T on the plus strand) conferred OR=1.22 (95% CI 1.05–1.41) in the dominant model and OR=1.26 (95% CI 1.07–1.47) in the heterozygote model for diabetic retinopathy, with risk present in both Asian and Caucasian subgroups. Abdel-Azeez et al. (2009)⁷⁷ Abdel-Azeez et al. (2009)
Abdel-Azeez HA et al. Association of the RAGE −374 T/A gene polymorphism and circulating soluble RAGE with nephropathy in type 1 diabetic patients. Egypt J Immunol, 2009 found OR=2.36 (95% CI 1.1–5.6) for the −374A coding allele (T plus strand) predicting diabetic nephropathy (n=70), with sRAGE levels paradoxically elevated in nephropathy patients — a marker of inflammatory burden rather than protection at that stage of disease.

Cardiovascular disease. In non-diabetic contexts, findings diverge. Falcone et al. (2004)⁸⁸ Falcone et al. (2004)
Falcone C et al. Relationship between the −374T/A RAGE gene polymorphism and angiographic coronary artery disease. Int J Mol Med, 2004 showed in 259 non-diabetic Italians that the −374AA coding genotype (plus-strand TT) was independently protective against angiographically confirmed CAD (OR=0.33, 95% CI 0.15–0.73, p=0.006) — found in 22.6% of controls but only 9.7% of CAD patients. This likely reflects the sRAGE-elevating effect of higher RAGE transcription in a non-AGE-overloaded context. Conversely, Aslan et al. (2024)⁹⁹ Aslan et al. (2024)
Aslan EI et al. Receptor for advanced glycation end products polymorphisms in coronary artery ectasia. Gene, 2024 found that the −374A coding allele (T plus strand) was independently associated with coronary artery ectasia¹⁰¹⁰ coronary artery ectasia
Abnormal dilation of coronary arteries — a distinct clinical entity from obstructive CAD, associated with impaired endothelial function and platelet activation (p<0.001, AUC=0.713 for discrimination), suggesting that in certain vascular phenotypes the elevated RAGE expression drives pathological remodeling.

Type 1 diabetes with poor metabolic control. Pettersson-Fernholm et al. (2003)¹¹¹¹ Pettersson-Fernholm et al. (2003)
Pettersson-Fernholm K et al. The functional −374 T/A RAGE gene polymorphism is associated with proteinuria and cardiovascular disease in type 1 diabetic patients. Diabetes, 2003 found in 996 Finnish T1D patients with HbA1c >9.5% that the −374AA coding genotype (TT on plus strand) was paradoxically protective: 30% had normal albumin excretion vs 10% in TT+TA coding carriers (p=0.01), and rates of CHD (6% vs 14%) and MI (2% vs 14%) were markedly lower. In this extreme glycemic environment, the highest sRAGE producers (TT plus strand) may maintain enough decoy activity to partially offset the AGE burden.

A note on the evidence paradox. The literature on −374T/A contains genuine heterogeneity: the same functional allele appears protective in non-diabetic cardiovascular studies and in poorly controlled T1D, yet harmful in diabetic retinopathy meta-analyses. The likely explanation is that sRAGE and membrane RAGE co-scale with RAGE expression, and their net effect depends critically on the ambient AGE load. The evidence level for this SNP is rated moderate, not strong, because of these context-dependent inconsistencies. Single-genotype actions focus on the best-replicated risk associations (diabetic microvascular complications), where multiple cohorts and a meta-analysis converge.

Practical Actions

The actionable consequence of carrying the T plus-strand allele (−374A coding) depends on metabolic context. For users with normal glucose metabolism, the clinical significance of this SNP alone is modest; the main priority is protecting against future hyperglycemia, which would convert the elevated RAGE expression from a complex mixed signal into a clear-cut driver of microvascular damage. For anyone with prediabetes or diabetes, this variant is a strong reason to pursue tight glycemic control and regular screening for early microvascular complications (retina, kidney).

Dietary advanced glycation end-products — formed by high-heat cooking and abundant in processed foods — add to endogenous AGE production and further activate RAGE-signaling. Reducing dietary AGE intake through cooking method changes (moist heat over dry high-heat) is the most directly mechanism-specific intervention available for RAGE pathway variants.

Interactions

rs1800624 is frequently co-analyzed with rs2070600 (Gly82Ser) as part of an AGER haplotype. Peng et al. (2022)¹²¹² Peng et al. (2022)
Peng Y et al. Genetically modified circulating levels of AGEs and their soluble receptor with risk and mortality of breast cancer. Cancers, 2022 showed that rs2070600 and rs1800624 together dose-dependently predict sRAGE levels, and specific haplotype combinations interact with high AGE exposure to confer breast cancer risk. Users carrying both the rs2070600 T allele (reduced sRAGE shedding) and rs1800624 T allele (elevated total RAGE expression) may experience compounding effects on the AGE-RAGE axis — elevated RAGE surface density with impaired sRAGE buffering simultaneously. This combination warrants a compound action covering both variants (see interaction_candidates below).

Interleukin-6 (IL-6) is one of the most versatile signalling molecules in the human body. Produced by immune cells, fat tissue, and — critically — by working skeletal muscle, it acts as both a pro-inflammatory cytokine¹¹ pro-inflammatory cytokine
a signalling protein that promotes inflammation as part of the immune response and an anti-inflammatory myokine²² myokine
a cytokine released by muscle fibres during contraction, with systemic metabolic effects. The -174G/C promoter variant (rs1800795) sits 174 base pairs upstream of the IL6 gene on chromosome 7 and directly controls how much IL-6 your cells produce.

The Mechanism

The G allele at position -174 creates a promoter sequence with higher transcriptional activity³³ transcriptional activity
the rate at which a gene is read and converted into mRNA, which then becomes protein. In reporter gene assays, the G allele drives roughly 2-fold higher IL6 transcription compared to the C allele. This difference is mediated by a binding site for the transcription factor NF-1⁴⁴ NF-1
Nuclear Factor 1, a transcription factor that represses IL6 expression when bound to the -174C sequence: the C allele creates this repressive binding site, while the G allele abolishes it, allowing uninhibited transcription.

The consequence is straightforward: GG homozygotes produce the most IL-6 at baseline and under stress, CG heterozygotes produce intermediate amounts, and CC homozygotes produce the least. After stimulation by LPS⁵⁵ LPS
lipopolysaccharide, a bacterial endotoxin that triggers immune activation or IL-1, the G allele construct shows a robust increase in expression while the C allele construct remains largely unresponsive.

The Evidence

The -174G/C variant is one of the most studied cytokine polymorphisms, with evidence spanning cardiovascular disease, diabetes, exercise physiology, and ageing.

Cardiovascular risk: A meta-analysis of 74 studies with 86,229 subjects⁶⁶ meta-analysis of 74 studies with 86,229 subjects
Rodriguez-Perez et al. Interleukin 6 (rs1800795) gene polymorphism is associated with cardiovascular diseases. EXCLI Journal, 2019 found the C allele associated with increased cardiovascular disease risk (dominant model OR 1.12, 95% CI 1.07-1.18). The association was strongest for coronary artery disease (homozygous OR 1.50) and in Chinese populations (allelic OR 1.36).

Exercise-induced muscle damage: Yamin et al.⁷⁷ Yamin et al.
IL6 (-174) and TNFA (-308) promoter polymorphisms are associated with systemic creatine kinase response to eccentric exercise. Eur J Appl Physiol, 2008 demonstrated that CC homozygotes had a greater than 3-fold increased risk of massive creatine kinase⁸⁸ creatine kinase
an enzyme released from damaged muscle fibres; elevated CK after exercise is a marker of muscle damage (CK) response following eccentric exercise. Paradoxically, despite producing less IL-6 at baseline, the CC genotype appears to mount a more exaggerated muscle damage response.

Power athlete association: Ruiz et al.⁹⁹ Ruiz et al.
The -174 G/C polymorphism of the IL6 gene is associated with elite power performance. J Sci Med Sport, 2010 found the GG genotype overrepresented among elite power athletes (sprinters, jumpers, throwers) with an OR of 2.47 compared to controls, suggesting the higher inflammatory response may benefit explosive performance.

Diabetes: A comprehensive meta-analysis of 42,150 participants¹⁰¹⁰ comprehensive meta-analysis of 42,150 participants
IL-6 gene rs1800795 polymorphism and diabetes mellitus. Diabetol Metab Syndr, 2022 found the G allele associated with decreased type 2 diabetes risk in some populations, while the C allele showed a protective effect against fasting hyperglycaemia.

Glucose metabolism: A joint analysis of 17 studies¹¹¹¹ joint analysis of 17 studies
Huth et al. Joint analysis of individual participants' data from 17 studies on the association of the IL6 variant -174G>C. Ann Med, 2009 found C-allele carriers had significantly lower fasting glucose (-0.091 mmol/L, P=0.014).

Practical Implications

The functional consequence of this variant — higher or lower IL-6 production — has different implications depending on context:

For exercise recovery, GG carriers mount a stronger inflammatory response to training, which may support adaptation for power sports but also means managing recovery is important. CC carriers, despite lower baseline IL-6, show elevated muscle damage markers after eccentric exercise and may need longer recovery between intense sessions.

For cardiovascular health, the C allele carries modestly increased risk, making anti-inflammatory lifestyle measures and regular monitoring more relevant for CC and CG individuals.

For metabolic health, the C allele is associated with slightly lower fasting glucose, offering a minor metabolic advantage, while the G allele may carry a modest type 2 diabetes risk in certain populations.

Anti-inflammatory strategies — omega-3 fatty acids, adequate sleep, managing chronic stress, and maintaining a diet rich in colourful vegetables and polyphenols — are beneficial for all genotypes but especially important for GG carriers with higher baseline inflammation.

Interactions

The -174G/C variant (rs1800795) is in strong linkage disequilibrium with rs1800797 (-597G/A) in the same IL6 promoter region (r-squared = 0.92), meaning these two variants are almost always inherited together. The nearby rs1800796 (-572G/C) variant is an independent functional polymorphism that can compound the effect on IL-6 levels, though it is primarily polymorphic in East Asian populations. IL-6 signalling also interacts with the broader inflammatory cascade — TNF-alpha and CRP levels are influenced by IL-6, so this variant has downstream effects on systemic inflammation markers.

The complement factor H gene (CFH) on chromosome 1q31.3 is one of the most well-studied genetic determinants of age-related macular degeneration (AMD) — the leading cause of irreversible blindness in adults over 65. rs1831281 is an intronic variant at position 196,711,684 (GRCh38) in intron 10 of CFH, annotated at transcript position c.1337-2051. Like several other CFH intronic variants (rs551397, rs1329428, rs1410996), it serves as a haplotype tag SNP¹¹ haplotype tag SNP
a genetic marker that travels with a cluster of risk variants across generations because of their proximity on the chromosome, marking the complement-risk haplotype architecture of the CFH gene.

The C allele is both the GRCh38 reference allele and the major allele, found in ~80% of Europeans. Despite being common, it tags the complement-risk haplotype — a well-documented pattern in the CFH region where the ancestral, common haplotype carries the AMD-risk configuration. The T allele (~20% in Europeans, ~10% in Africans, ~39% in East Asians) marks the protective haplotype and is associated with better complement regulation at the retina and other tissues.

The Mechanism

Complement Factor H²² Complement Factor H
a 155 kDa plasma glycoprotein that is the primary fluid-phase regulator of the alternative complement pathway works by binding C3b (the activated form of complement component 3) and accelerating the decay of the amplification convertase C3bBb. At mucosal surfaces — including the retinal pigment epithelium (RPE) and Bruch's membrane — CFH suppresses chronic, low-grade complement activation that would otherwise damage host tissue. Age-related accumulation of oxidized lipids, advanced glycation end-products, and cellular debris provides a progressive stimulus for complement activation in the sub-retinal space.

rs1831281 itself does not alter any amino acid. Its disease significance comes from linkage disequilibrium with functionally important variants in the surrounding CFH haplotype block — principally the well-characterized complement-risk alleles at rs551397 (intron 1), rs1329428 (intron 14), and the coding missense variant Y402H (rs1061170, exon 9). The C allele at rs1831281 travels on the same chromosome as the risk alleles at these adjacent positions; by carrying the C allele, a person is statistically more likely to also carry the full complement-risk haplotype configuration, which cumulatively reduces CFH's protective function at retinal and other complement-exposed surfaces.

A correction notice was issued for the Hughes et al. 2006 Nature Genetics study³³ Hughes et al. 2006 Nature Genetics study
A common CFH haplotype, with deletion of CFHR1 and CFHR3, is associated with lower risk of age-related macular degeneration. Nature Genetics 2006 regarding the allele designations of rs1831281 in Figure 1, confirming that this SNP was genotyped and used in CFH haplotype block analyses of AMD risk.

The Evidence

The AMD association of the CFH locus is one of the most replicated findings in complex disease genetics. Klein et al. 2005⁴⁴ Klein et al. 2005
Science — genome-wide screen of 116,000+ SNPs in 96 cases and 50 controls identified the CFH intronic region as the primary AMD susceptibility locus, with homozygous risk carriers showing a 7.4-fold increased likelihood of AMD. The CFH haplotype block where rs1831281 resides (intron 10, c.1337-2051) is part of this broader risk architecture.

Hageman et al. 2005⁵⁵ Hageman et al. 2005
PNAS — 900 AMD cases and controls further characterized the CFH risk haplotype, finding it in 50% of AMD cases versus 29% of controls (OR 2.46), with homozygous risk carriers comprising 24% of cases but only 8% of controls. Critically, risk and protective haplotypes were identified across the entire CFH gene including its intronic regions — the same structure encompassing rs1831281.

The large Lu et al. 2018 meta-analysis⁶⁶ Lu et al. 2018 meta-analysis
53 studies, 53,774 AMD patients, 56,973 controls. Genet Test Mol Biomarkers 2018 demonstrated that T-allele carrying CFH haplotype SNPs in this region are associated with OR=0.53 for AMD protection (95% CI 0.45–0.61), underscoring the magnitude of protection conferred by the complement-protective haplotype to which the T allele of rs1831281 belongs.

Regarding cardiovascular disease, the Sofat et al. 2010 meta-analysis⁷⁷ Sofat et al. 2010 meta-analysis
~48,000 participants, 9,097 CHD cases found that CFH genotype was not associated with coronary heart disease (pooled OR 1.02, 95% CI 0.91–1.13 for the Y402H risk allele). This meta-analysis result is expected to extend to other CFH haplotype-tag SNPs including rs1831281: the complement-inflammation pathway operates through AMD-specific retinal mechanisms rather than classical atherosclerotic pathways.

Practical Actions

The C allele at rs1831281 is clinically useful primarily as part of a multi-variant CFH risk profile. Its significance is amplified when co-occurring with risk alleles at rs1061170 (Y402H), rs551397, and rs800292 — and diminished when the protective T allele is present, which partially offsets the complement-risk haplotype background.

For CC homozygotes, the primary actionable implications are identical to those for other CFH complement-risk haplotype SNPs: earlier ophthalmologic surveillance, targeted macular carotenoid supplementation, and omega-3 optimization to reduce complement-driven retinal inflammation. Smoking cessation is particularly important as tobacco compounds CFH-pathway complement activation at the retina through oxidative and endothelial mechanisms.

Interactions

rs1831281 is in linkage disequilibrium with multiple CFH haplotype SNPs across the gene: rs551397 (intron 1), rs1329428 (intron 14), and the Y402H coding variant rs1061170. The AMD-risk C allele at rs1831281 is expected to co-occur with the risk alleles at these positions in most chromosomes carrying the risk haplotype, making it an additive signal rather than an independent risk factor. The most clinically meaningful two-locus interaction is with ARMS2 (rs10490924), where complement dysregulation (CFH) plus retinal oxidative stress (ARMS2) converge on two independent AMD pathogenesis pathways with synergistic risk elevation.

Interleukin-6 is the cytokine most consistently elevated in older adults — a key driver of inflammaging¹¹ inflammaging
the chronic low-grade inflammation that accumulates with age and underlies most age-related diseases, from atherosclerosis to Alzheimer's to type 2 diabetes. Within the IL6 gene lies a lesser-known intronic variant, rs2069837, whose effect on aging biology is not what you might expect: rather than directly changing IL-6 protein structure or promoter activity, it operates through a remarkable long-range genomic mechanism that reaches half a megabase away.

The Mechanism

rs2069837 sits in intron 2 of IL6, within an active enhancer region²² enhancer region
a stretch of non-coding DNA that can dramatically increase or decrease expression of target genes, often over large genomic distances. In 2019, researchers discovered that this variant doesn't primarily regulate IL6 itself — it regulates GPNMB³³ GPNMB
glycoprotein NMB, an anti-inflammatory protein expressed in macrophages that dampens immune overactivation and promotes tissue resolution, located approximately 520 kilobases away on the same chromosome.

The mechanism operates through chromatin looping: CTCF⁴⁴ CTCF
CCCTC-binding factor, a structural protein that creates physical contact points between distant genomic regions mediates a long-range interaction that brings the rs2069837 enhancer into physical contact with the GPNMB promoter. The A allele of rs2069837 preferentially recruits the MEF2-HDAC repressive complex⁵⁵ MEF2-HDAC repressive complex
a protein complex that silences gene expression by compacting chromatin into a transcriptionally inactive state, suppressing GPNMB expression in monocyte-derived macrophages. The G allele disrupts this repressive recruitment, allowing GPNMB to be expressed normally. ⁶⁶ Kong et al. Takayasu arteritis risk locus in IL6 represses the anti-inflammatory gene GPNMB through chromatin looping and recruiting MEF2-HDAC complex. Ann Rheum Dis, 2019

The downstream consequence is that A-allele carriers have lower macrophage GPNMB expression, which in turn alters the balance of IL-6 signalling — the A allele environment allows higher effective IL-6 activity because the anti-inflammatory brake (GPNMB) is partially removed. The G allele restores the brake.

The Evidence

Longevity GWAS: A genome-wide association study in Han Chinese centenarians⁷⁷ genome-wide association study in Han Chinese centenarians
Zeng et al. Novel loci and pathways significantly associated with longevity. Scientific Reports, 2016 found rs2069837 reached genome-wide significance (P = 1.80 × 10⁻⁹) as a longevity locus, with the G allele significantly less frequent among centenarians than among middle-aged controls (OR = 0.61). This indicates the G allele is paradoxically the longevity-deleterious allele at this locus — those who live longest tend to carry more A alleles.

COVID-19 severity: The G allele's effect on GPNMB/IL-6 has an acute protective benefit in some inflammatory contexts. A GWAS of critical COVID-19⁸⁸ GWAS of critical COVID-19
Gong et al. A genetic variant in IL-6 lowering its expression is protective for critical patients with COVID-19. Signal Transduct Target Ther, 2022 found G-allele carriers had dramatically lower risk of critical illness (OR = 0.41 in discovery cohort; OR = 0.49 in combined analysis, P = 4.64 × 10⁻¹⁶). The mechanism confirmed: the G allele decreased MEF2a binding and increased GPNMB expression, resulting in lower IL-6. The protective effect was stronger in males.

Hepatocellular carcinoma: In the context of chronic liver disease, the G allele confers risk rather than protection. A meta-analysis of 13 case-control studies⁹⁹ meta-analysis of 13 case-control studies
Emami Aleagha et al. Association between IL-6 polymorphisms and HCC susceptibility. Clin Exp Hepatol, 2020 found the GG genotype associated with 2.25-fold elevated hepatocellular carcinoma risk (OR 2.25, 95% CI 1.18–4.29). This aligns with GPNMB's dual roles: GPNMB suppresses inflammatory tissue damage, but also blunts immune surveillance against tumour cells.

Alzheimer's disease: A Taiwanese case-control study¹⁰¹⁰ Taiwanese case-control study
Chen et al. Sequence variants of IL-6 are significantly associated with a decreased risk of late-onset Alzheimer's disease. J Neuroinflammation, 2012 analyzed IL6 haplotypes including rs2069837 in 266 AD cases and 444 controls. The strongest protective signal (adjusted OR = 0.65) came from a haplotype defined by rs1800796 and rs1524107 rather than rs2069837 directly. Hypertension significantly modified the association.

Practical Implications

This variant presents a genuine paradox: the G allele protects against acute inflammatory overreaction (severe COVID-19, autoimmune vasculitis) but is underrepresented among extreme long-livers in East Asian populations and associates with elevated hepatocellular carcinoma risk. This reflects GPNMB's dual nature — an anti-inflammatory signal that also dampens immune surveillance.

For AA homozygotes (the genotype of most centenarians), lower GPNMB expression maintains stronger macrophage inflammatory tone. This may be advantageous for cancer immune surveillance and, over decades, for the type of calibrated immune competence associated with exceptional longevity. However, the tradeoff is potentially higher IL-6 activity, making monitoring of inflammatory markers and IL-6-related disease risk more important.

For AG heterozygotes, intermediate GPNMB expression places them between the extremes. The clinical implications are modest and context-dependent.

For GG homozygotes (rare, ~1% of most populations), higher GPNMB suppresses IL-6 and may offer protection in acute inflammatory settings, but the rare homozygous state has been associated with elevated HCC risk and is uncommon in centenarians.

Interactions

rs2069837 exists within the broader IL6 gene context alongside the well-characterised promoter variant rs1800795 (-174G/C), which is in the GeneOps database under the fitness-body category. These two variants operate through distinct mechanisms and are not in strong linkage disequilibrium — rs1800795 affects promoter transcriptional activity directly, while rs2069837 acts through the distal GPNMB enhancer loop. Combined effects of rs1800795 (direct IL-6 production) and rs2069837 (GPNMB-mediated IL-6 modulation) on inflammaging have not been formally studied as a compound genotype. The interaction with IL-10 variants (particularly rs1800871) has been studied in epidemiological contexts, with IL6 rs2069837 × IL10 haplotype combinations showing region-specific effects on disease susceptibility.

SREBP-2 (sterol regulatory element-binding protein 2), encoded by the SREBF2 gene on chromosome 22, is the master transcription factor of cholesterol homeostasis. It directly controls expression of HMGCR¹¹ HMGCR
HMG-CoA reductase — the rate-limiting enzyme in cholesterol biosynthesis and the target of all statin drugs, LDLR²² LDLR
the LDL receptor that clears LDL cholesterol from the bloodstream, and more than 30 other genes in the cholesterol synthesis and uptake pathways. The rs2228314 variant (G1784C) is a missense change that substitutes glycine for alanine at protein position 595 and has been linked to cardiovascular disease risk and altered cholesterol regulation across multiple populations.

The Mechanism

The Gly595Ala substitution falls in the carboxyl-terminal regulatory domain of SREBP-2, the region that physically interacts with SCAP³³ SCAP
SREBP cleavage-activating protein — the sterol sensor that escorts SREBP-2 from the ER to the Golgi for proteolytic activation. Under normal cholesterol conditions, SCAP holds SREBP-2 anchored to the endoplasmic reticulum membrane, suppressing transcriptional activity. When cellular cholesterol falls — as happens during statin treatment — SCAP escorts SREBP-2 to the Golgi, where it is cleaved and the active transcription factor enters the nucleus to upregulate HMGCR, LDLR, and other cholesterol-response genes.

The Gly595Ala change is located at a position in the C-terminal domain involved in SCAP WD-repeat interactions. Bioinformatic analysis suggests the mutation position is not strongly conserved, but in vitro studies show the Ala-595 isoform may diminish SREBF2 proteolytic cleavage⁴⁴ diminish SREBF2 proteolytic cleavage
Haas et al. — the p.A595G (C allele) polymorphism diminishes SREBF2 cleavage in vitro and is associated with higher cholesterol levels in polygenic hypercholesterolemia, potentially blunting the cholesterol-sensing feedback loop.

The Evidence

A study of early-onset myocardial infarction⁵⁵ study of early-onset myocardial infarction
Friedlander et al. SREBP-2 and SCAP isoforms and risk of early onset myocardial infarction. Atherosclerosis, 2008 in 257 women and 320 men (ages 18–59 for women, 18–49 for men) found that women homozygous for the 595A (Ala, C allele) isoform had nearly twice the risk of a first MI compared to 595G homozygotes (OR 1.95, 95% CI 1.07–3.54). In men, the 595A isoform was associated with increased MI risk per-allele (OR 1.63, 95% CI 1.26–2.12), with the effect modified by the co-inherited SCAP 2386A>G variant.

A sudden cardiac death study⁶⁶ sudden cardiac death study
Nakhjavani et al. Expression of SREBF2 and SCAP in human atheroma and association with sudden cardiac death. Thrombosis Journal, 2009 found that men carrying both the SREBF2 C allele and the SCAP G allele (rs12487736) had a 2.68-fold elevated risk of SCD (95% CI 1.07–6.71, p=0.035) compared to those carrying C allele alone, pointing to a gene-gene interaction that amplifies cardiovascular risk.

A case-control study⁷⁷ case-control study
Vargas-Alarcon et al. SREBF1c and SREBF2 gene polymorphisms and acute coronary syndrome in Mexican population. PLoS One, 2019 in 614 ACS patients and 689 healthy controls of Mexican-Amerindian descent found the G allele associated with ACS risk under recessive (OR 1.78, p=0.03) and additive (OR 1.27, p=0.04) models. The apparent reversal — G risk in Mexicans versus C risk in Europeans — likely reflects the fact that the G allele is the minor allele in Latino populations (~35%), where homozygous GG individuals represent a distinct risk stratum, while C is minor in Europeans (~26%).

A carotid intima-media thickness study⁸⁸ carotid intima-media thickness study
characterization of SREBP-2 gene polymorphisms: role in atherosclerosis. Atherosclerosis, 2003 in 655 asymptomatic men found the 1784G>C variant significantly associated with increased IMT — a marker of subclinical atherosclerosis — without detectable changes in plasma lipid levels, suggesting the variant may influence vascular risk through mechanisms beyond simple LDL elevation.

A NAFLD study⁹⁹ NAFLD study
Wang et al. Relationship of SREBP-2 rs2228314 G>C polymorphism with NAFLD in Han Chinese. Genet Test Mol Biomarkers, 2014 found homozygous GG genotype associated with increased risk of non-alcoholic fatty liver disease in 300 NAFLD cases versus 160 controls (p<0.001), suggesting the variant may also influence hepatic lipid accumulation through SREBP-2 target gene dysregulation.

ClinVar classifies the C (alternate) allele as benign based on population frequency data, with no pathogenic submissions. The clinical associations above are from GWAS and case-control studies — this variant is a risk modifier, not a disease-causing mutation.

Practical Actions

Carriers of the C allele at this locus, particularly those homozygous (CC), may have a subtly altered cholesterol-sensing feedback loop. Monitoring LDL cholesterol and tracking response to dietary changes or statin therapy is a reasonable proactive step. Those with the CC genotype may show attenuated statin response compared to GG individuals, given SREBP-2's central role in statin-induced LDLR upregulation — though the clinical evidence for this specific pharmacogenomic interaction is still emerging.

Dietary phytosterols (plant sterols/stanols from fortified foods or supplements) provide an additional cholesterol-lowering pathway that does not depend on SREBP-2 activity, making them a relevant strategy for CC genotype carriers who want to augment cholesterol management.

Interactions

The most clinically relevant interaction is with SCAP rs12487736 (2386A>G). The SCAP protein is the direct chaperone and sterol sensor for SREBP-2; variants in SCAP that alter its interaction with SREBP-2 compound the effect of this variant. Carrying risk alleles at both SREBF2 rs2228314 and SCAP rs12487736 appears to substantially elevate sudden cardiac death risk in men (OR 2.68), beyond what either variant contributes alone. This gene-gene interaction is a strong candidate for a compound action.

This variant also sits in the same cholesterol-homeostasis pathway as APOE (rs429358, rs7412). APOE E4 carriers who also carry the SREBF2 C allele may have compounded LDL clearance impairment — the APOE variant impairs LDL receptor binding affinity while the SREBF2 variant may blunt transcriptional upregulation of LDLR expression.

The ATG16L1 gene provides instructions for making a protein essential to autophagy, the cellular recycling system that clears out damaged components and invading bacteria. The T300A variant¹¹ The T300A variant
This threonine-to-alanine substitution at position 300 is one of the most replicated genetic risk factors for Crohn's disease, first identified in a genome-wide association study in 2007 and subsequently confirmed in dozens of independent cohorts worldwide. In the gut, ATG16L1 plays a critical role in Paneth cells, specialized epithelial cells that secrete antimicrobial peptides and maintain the intestinal barrier. The T300A variant impairs this function, allowing bacteria to persist when they would normally be destroyed.

The Mechanism

The T300A variant sits near a caspase-3 cleavage site²² The T300A variant sits near a caspase-3 cleavage site
Amino acids 296-299 form a caspase cleavage motif, and the T300A substitution significantly increases the protein's susceptibility to caspase-3-mediated degradation during cellular stress. When cells experience metabolic stress, death receptor activation, or starvation, caspase-3 degrades the T300A variant more rapidly than wild-type ATG16L1, resulting in diminished autophagy. This leaves epithelial cells less able to clear invading bacteria like Salmonella and Yersinia enterocolitica. Studies in human epithelial cells show the T300A variant has markedly decreased efficiency³³ the T300A variant has markedly decreased efficiency
The ala300-containing variant showed decreased capture of internalized Salmonella within autophagosomes compared to the wildtype thr300-containing variant in capturing bacteria within autophagosomes. The variant also disrupts the WD40 domain's ability to interact with proteins like TMEM59, further impairing unconventional autophagy pathways.

The Evidence

Multiple meta-analyses confirm the T300A association with Crohn's disease⁴⁴ Multiple meta-analyses confirm the T300A association with Crohn's disease
Meta-analysis of 30,606 IBD patients found the G allele was a risk factor (OR 1.23, 95% CI: 1.09-1.39, p=0.001) while the A allele was protective (OR 0.74, 95% CI: 0.72-0.77, p<0.001). The association is strongest in Caucasian populations from North America, Europe, and Latin America, with minimal to no association observed in Asian populations. CD patients carrying the G allele are significantly more predisposed to perianal disease⁵⁵ CD patients carrying the G allele are significantly more predisposed to perianal disease
OR 1.21, 95% CI: 1.07-1.38, p=0.003, one of the more severe and treatment-resistant manifestations of Crohn's. A 2025 meta-analysis found the G allele increases CD risk worldwide⁶⁶ A 2025 meta-analysis found the G allele increases CD risk worldwide
OR 1.33, 95% CI: 1.29-1.37, with GG homozygotes showing higher risk than AG heterozygotes. The variant also alters gut microbiota composition—studies in knock-in mice show increased Bacteroides ovatus and elevated Th17 and Th1 immune cells⁷⁷ studies in knock-in mice show increased Bacteroides ovatus and elevated Th17 and Th1 immune cells
Changes occur before disease onset, suggesting T300A contributes to dysbiosis and immune infiltration prior to symptoms.

Practical Implications

This variant doesn't cause Crohn's disease on its own—it's a susceptibility factor that increases risk in the presence of environmental triggers like smoking, certain infections, or dietary patterns that stress the gut. For those with the GG genotype (about 19% of Europeans), maintaining gut barrier integrity becomes especially important. This means prioritizing dietary fiber, fermented foods, and avoiding pro-inflammatory processed foods and excessive antibiotic use. Regular monitoring for early signs of inflammatory bowel disease (persistent diarrhea, abdominal pain, blood in stool) allows for earlier intervention. The variant's impact on bacterial clearance also suggests that individuals with GG may benefit from strategies that support innate immunity and gut microbial diversity.

Interactions

ATG16L1 T300A interacts with other Crohn's disease susceptibility genes through multiple pathways. Multidimensionality reduction analysis shows interaction between ATG16L1, IBD5 (rs6596075), and IL23R (rs10889677) risk alleles⁸⁸ Multidimensionality reduction analysis shows interaction between ATG16L1, IBD5 (rs6596075), and IL23R (rs10889677) risk alleles
MDR analysis suggested an interaction between IBD5, ATG16L1, and IL23R risk alleles, with combined carriage of multiple risk variants substantially increasing CD risk. NOD2 (rs17221417) is particularly important— NOD2 recruits ATG16L1 to sites of bacterial entry⁹⁹ NOD2 recruits ATG16L1 to sites of bacterial entry, so NOD2 mutations combined with ATG16L1 T300A produce a synergistic defect in bacterial autophagy. Individuals homozygous for risk alleles at ATG16L1, IBD5, and NOD2 face approximately 20-fold higher CD risk¹⁰¹⁰ Individuals homozygous for risk alleles at ATG16L1, IBD5, and NOD2 face approximately 20-fold higher CD risk
OR 20.4, CI 8.71-47.7 compared to those carrying none of these variants. IL23R variants also show statistical interaction, as IL23R regulates the Th17 immune response that becomes dysregulated when ATG16L1-mediated bacterial clearance fails.